Chronic Myeloid Leukemia

Managing Patients With Myeloid Malignancies During and After the Global COVID-19 Pandemic

June 24, 2020

During the Virtual 25th Congress of the European Hematology Association (EHA), a group of physicians described their experiences and recommendations for managing patients with myeloid malignancies during the COVID-19 pandemic and after.

Unmet Needs Researchers are Investigating in Chronic Myeloid Leukemia

April 22, 2020

Michael J. Mauro, MD, discusses the unmet needs of patients with chronic myeloid leukemia and what potential therapies are being investigated currently for this patient population.

Weighing Risks and Benefits With the Use of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

September 20, 2019

Q&A With Moshe Yair Levy, MD: Weighing Risks and Benefits With the Use of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

September 20, 2019

Chronic myeloid leukemia is a rare type of cancer, and tyrosine kinase inhibitors have become the standard guideline-recommended treatment for patients with BCR-ABL1–positive or Ph-positive CML.

BCL2 Inhibition in Leukemia

June 25, 2019

Leukemia

BCR-ABL1 TKIs in Relapsed/Refractory CML

June 24, 2019

Chronic Myeloid Leukemia

PFS and EFS Extended With Ibrutinib Monotherapy in Early-Stage CLL

June 18, 2019

Patients with early-stage, asymptomatic, newly diagnosed chronic lymphocytic leukemia showed improved survival outcomes with ibrutinib monotherapy compared with placebo, according to results from phase III CLL12 study presented at the 2019 European Hematology Association Congress.

Acalabrutinib Plus Obinutuzumab Prompts High Response Rate in Patients with CLL

June 05, 2019

Patients with chronic lymphocytic leukemia showed high responses when given a combination of acalabrutinib and obinutuzumab, which targets BTK and the CD20 antigen. High response rates over 90% were seen across various settings of disease, according to the results of a small, preliminary trial.

Venetoclax/Obinutuzumab Combo Advances PFS in Previously Untreated CLL

June 05, 2019

According to the pivotal phase III CLL14 study presented during the 2019 American Society of Clinical Oncology Annual Meeting, venetoclax plus obinutuzumab demonstrated a lengthening in progression-free survival time for patients with previously untreated chronic lymphocytic leukemia compared with obinutuzumab plus chlorambucil. Trial results show that the chemotherapy-free combination reduced the risk for disease worsening or death by 65% compared with obinutuzumab plus chlorambucil.

Chronic Myeloid Leukemia

May 28, 2019

Chronic Myeloid Leukemia